Paper Details

  1. Home
  2. Paper Details

Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.

Author: DeykinAaron, MatsonMark A, TangYongqiang, TuccilloDianne, ZimmermanThomas R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of dose titration on flu-like symptoms, a common side effect of interferon beta therapy. The study found that dose titration was effective in reducing the severity and incidence of flu-like symptoms during the initial 8 weeks of treatment.
Paper Details　
Original Abstract of the Article :
Flu-like symptoms (FLS) are common side effects of interferon beta (IFNβ) therapy and can negatively affect the willingness of patients with multiple sclerosis to initiate therapy. Although dose titration is commonly used to reduce the severity and incidence of IFNβ-related FLS during treatment init...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007995.2011.630720

データ提供：米国国立医学図書館（NLM）

Interferon Beta-1a: A Journey Through the Desert of Multiple Sclerosis

The desert of multiple sclerosis (MS) can be a challenging landscape, often marked by debilitating symptoms. Interferon beta (IFNβ) therapy offers a lifeline for many patients, but it can come with its own set of side effects, including flu-like symptoms (FLS). This research investigates the potential of dose titration to reduce the severity and incidence of FLS during treatment initiation. The researchers conducted a randomized, dose-blinded, parallel-group study to assess the effectiveness of this approach. Their goal is to find a way to make the journey through the desert of MS treatment more manageable and comfortable for patients.

A Smoother Path Through the Sands

The results of this study demonstrate that dose titration of intramuscular interferon beta-1a can effectively reduce the severity and incidence of flu-like symptoms during treatment initiation. This finding offers a valuable strategy for improving patient compliance and reducing the burden of side effects associated with IFNβ therapy.

A More Comfortable Journey

This research highlights the importance of personalized approaches to MS treatment. By carefully adjusting the dose of IFNβ therapy, we can create a more comfortable and manageable experience for patients. This can encourage greater adherence to treatment and potentially lead to better long-term outcomes for individuals living with MS.

Dr.Camel's Conclusion

The desert of MS treatment can be a challenging journey, but this research offers a way to make the path smoother. Dose titration of interferon beta-1a can significantly reduce the burden of flu-like symptoms, making the experience more manageable for patients. This discovery is a reminder that even in the most challenging of landscapes, there are strategies to make the journey more comfortable and achievable.

Date :
  1. Date Completed 2012-03-21
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

21988668

DOI: Digital Object Identifier

10.1185/03007995.2011.630720

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.